Stephen Maxted Ansell, MD, PhD

  • 22799 Citations
  • 81 Scopus h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2018

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

Sonbol, M. B., Hilal, T., Dueck, A., Rosenthal, A. C., Conley, C. R., Kosiorek, H. E., Ginos, B. F., Gano, K. M., Nichols, C. S., Leis, J. F., Johnston, P. B., Habermann, T. M., Northfelt, D. W., Bergsagel, P. L., Inwards, D. J., Witzig, T. E., Ansell, S. M. & Reeder, C. B., Jan 11 2018, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-7 7 p.

Research output: Contribution to journalArticle

1 Scopus citations

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Bachy, E., Maurer, M. J., Habermann, T. M., Gelas-Dore, B., Maucort-Boulch, D., Estell, J. A., Van den Neste, E., Bouabdallah, R., Gyan, E., Feldman, A. L., Bargay, J., Delmer, A., Slager, S. L., da Silva, M. G., Fitoussi, O., Belada, D., Maisonneuve, H., Intragumtornchai, T., Ansell, S. M., Lamy, T. & 5 others, Dartigues, P., Link, B. K., Seymour, J. F., Cerhan, J. R. & Salles, G., Jul 5 2018, In : Blood. 132, 1, p. 49-58 10 p.

Research output: Contribution to journalArticle

28 Scopus citations

A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts

Ghesquières, H., Larrabee, B. R., Casasnovas, O., Maurer, M. J., McKay, J. D., Ansell, S. M., Montgomery, D., Asmann, Y. W., Farrell, K., Verney, A., Slager, S. L., Allmer, C., Perrot, A., Delarue, R., Habermann, T. M., Dupuis, J., Link, B. K., Canioni, D., Dogan, A., Cozen, W. & 3 others, Jarrett, R. F., Cerhan, J. R. & Salles, G., Jan 2018, In : British journal of haematology. 180, 2, p. 286-290 5 p.

Research output: Contribution to journalLetter

5 Scopus citations

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Paludo, J., Abeykoon, J. P., Shreders, A., Ansell, S. M., Kumar, S. K., Ailawadhi, S., King, R., Koehler, A. B., Reeder, C. B., Buadi, F. K., Dispenzieri, A., Lacy, M., Dingli, D. M., Witzig, T. E., Go, R. S., Gonsalves, W., Kourelis, T., Warsame, R., Leung, N., Habermann, T. M. & 6 others, Hayman, S., Lin, Y., Kyle, R. A., Rajkumar, S. V., Gertz, M. & Kapoor, P., Apr 3 2018, (Accepted/In press) In : Annals of Hematology. p. 1-9 9 p.

Research output: Contribution to journalArticle

15 Scopus citations

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

LaCasce, A. S., Gregory Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y. & Advani, R., Jul 5 2018, In : Blood. 132, 1, p. 40-48 9 p.

Research output: Contribution to journalArticle

45 Scopus citations

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L. & 9 others, Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D. & Radford, J., Jan 25 2018, In : New England Journal of Medicine. 378, 4, p. 331-344 14 p.

Research output: Contribution to journalArticle

182 Scopus citations
26 Scopus citations

Defining lymphoplasmacytic lymphoma: Does MYD88L265P define a pathologically distinct entity among patients with an IgM paraprotein and bone marrow-based low-grade b-cell lymphomas with plasmacytic differentiation?

Fang, H., Kapoor, P., Gonsalves, W., Frederick, L. A., Viswanatha, D., Howard, M. T., He, R., Morice, W. G., McPhail, E., Greipp, P. T., Ansell, S. M., Kyle, R. A., Gertz, M., Paludo, J., Abeykoon, J. & King, R., Jul 3 2018, In : American Journal of Clinical Pathology. 150, 2, p. 168-176 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials

Maurer, M. J., Ghesquières, H., Link, B. K., Jais, J. P., Habermann, T. M., Thompson, C. A., Haioun, C., Allmer, C., Johnston, P. B., Delarue, R., Micallef, I., Peyrade, F., Inwards, D. J., Ketterer, N., Farooq, U., Fitoussi, O., Macon, W. R., Molina, T. J., Syrbu, S., Feldman, A. L. & 8 others, Slager, S. L., Weiner, G. J., Ansell, S. M., Cerhan, J. R., Salles, G. A., Witzig, T. E., Tilly, H. & Nowakowski, G. S., Jun 1 2018, In : Journal of Clinical Oncology. 36, 16, p. 1603-1610 8 p.

Research output: Contribution to journalArticle

28 Scopus citations

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management

Ansell, S. M., May 1 2018, In : American Journal of Hematology. 93, 5, p. 704-715 12 p.

Research output: Contribution to journalArticle

18 Scopus citations

Hodgkin lymphoma

Younes, A., Dogan, A., Johnson, P., Yahalom, J., Kuruvilla, J. & Ansell, S. M., Nov 16 2018, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Wolters Kluwer Health Pharma Solutions (Europe) Ltd, p. 1649-1671 23 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Human Pegivirus infection and lymphoma risk and prognosis: A North American study

Fama, A., Xiang, J., Link, B. K., Allmer, C., Klinzman, D., Feldman, A. L., Nowakowski, G. S., Liebow, M., Larson, M. C., Maurer, M. J., Ansell, S. M., Novak, A. J., Asmann, Y., Slager, S. L., Call, T. G., Habermann, T. M., Cerhan, J. R. & Stapleton, J. T., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

9 Scopus citations

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Ansell, S. M., Jan 1 2018, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response

Ansell, S. M., Sep 1 2018, In : Cancer Journal (United States). 24, 5, p. 249-253 5 p.

Research output: Contribution to journalReview article

1 Scopus citations

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements

McPhail, E., Maurer, M. J., Macon, W. R., Feldman, A. L., Kurtin, P. J., Ketterling, R. P., Vaidya, R., Cerhan, J. R., Ansell, S. M., Porrata, L. F., Nowakowski, G. S., Witzig, T. E. & Habermann, T. M., Nov 1 2018, In : Haematologica. 103, 11, p. 1899-1907 9 p.

Research output: Contribution to journalArticle

14 Scopus citations
3 Scopus citations

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

Price-Troska, T., Yang, Z. Z., Diller, D., Bayden, A., Jarosinski, M., Audie, J. & Ansell, S. M., Apr 26 2018, (Accepted/In press) In : Investigational New Drugs. p. 1-8 8 p.

Research output: Contribution to journalArticle

In reply

Kapoor, P., Gertz, M. & Ansell, S. M., May 1 2018, In : JAMA oncology. 4, 5, p. 745-746 2 p.

Research output: Contribution to journalLetter

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., Ogden, C. A., Taft, D., Zhang, Q., Kato, K., Campbell, M. & Advani, R. H., Mar 15 2018, In : Blood. 131, 11, p. 1183-1194 12 p.

Research output: Contribution to journalArticle

93 Scopus citations
9 Scopus citations

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, G., Habermann, T. M. & 3 others, Witzig, T. E., Vitolo, U. & Nowakowski, G. S., Nov 1 2018, In : Blood Cancer Journal. 8, 11, 108.

Research output: Contribution to journalArticle

7 Scopus citations

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

Wenzl, K., Manske, M. K., Sarangi, V., Asmann, Y., Greipp, P. T., Schoon, H. R., Braggio, E. D., Maurer, M. J., Feldman, A. L., Witzig, T. E., Slager, S. L., Ansell, S. M., Cerhan, J. R. & Novak, A. J., Oct 1 2018, In : Blood Cancer Journal. 8, 10, 97.

Research output: Contribution to journalArticle

6 Scopus citations

Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma

Roemer, M. G. M., Redd, R. A., Cader, F. Z., Pak, C. J., Abdelrahman, S., Ouyang, J., Sasse, S., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Ansell, S. & 9 others, Kato, K., Farsaci, B., Sumbul, A., Armand, P., Neuberg, D. S., Pinkus, G. S., Ligon, A. H., Rodig, S. J. & Shipp, M. A., Apr 1 2018, In : Journal of Clinical Oncology. 36, 10, p. 942-950 9 p.

Research output: Contribution to journalArticle

76 Scopus citations

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Luchtel, R. A., Dasari, S., Oishi, N., Pedersen, M. B., Hu, G., Rech, K. L., Ketterling, R. P., Sidhu, J., Wang, X., Katoh, R., Dogan, A., Kip, N. S., Cunningham, J. M., Sun, Z., Baheti, S., Porcher, J. C., Said, J. W., Jiang, L., Hamilton-Dutoit, S. J., Møller, M. B. & 10 others, Nørgaard, P., Bennani, N. N., Chng, W. J., Huang, G., Link, B. K., Facchetti, F., Cerhan, J. R., D’Amore, F., Ansell, S. M. & Feldman, A. L., Sep 27 2018, In : Blood. 132, 13, p. 1386-1398 13 p.

Research output: Contribution to journalArticle

20 Scopus citations

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia

Abeykoon, J. P., Paludo, J., King, R., Ansell, S. M., Gertz, M., LaPlant, B. R., Halvorson, A. E., Gonsalves, W., Dingli, D. M., Fang, H., Rajkumar, S. V., Lacy, M., He, R., Kourelis, T., Reeder, C. B., Novak, A. J., McPhail, E., Viswanatha, D. S., Witzig, T. E., Go, R. S. & 10 others, Habermann, T. M., Buadi, F. K., Dispenzieri, A., Leung, N., Lin, Y., Thompson, C. A., Hayman, S. R., Kyle, R. A., Kumar, S. K. & Kapoor, P., Feb 1 2018, In : American Journal of Hematology. 93, 2, p. 187-194 8 p.

Research output: Contribution to journalArticle

22 Scopus citations

Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II checkmate 205 trial

Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Shipp, M. A., Kato, K., Sumbul, A., Farsaci, B. & Ansell, S. M., May 10 2018, In : Journal of Clinical Oncology. 36, 14, p. 1428-1439 12 p.

Research output: Contribution to journalArticle

149 Scopus citations

Outcomes among North American patients with diffuse large b-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Tracy, S. I., Habermann, T. M., Feldman, A. L., Maurer, M. J., Dogan, A., Perepu, U. S., Syrbu, S., Ansell, S. M., Thompson, C. A., Weiner, G. J., Nowakowski, G. S., Allmer, C., Slager, S. L., Witzig, T. E., Cerhan, J. R. & Link, B. K., Jan 31 2018, In : Haematologica. 103, 2, p. 297-303 7 p.

Research output: Contribution to journalArticle

7 Scopus citations

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness

He, R., Ding, W., Viswanatha, D. S., Chen, D., Shi, M., Van Dyke, D., Tian, S., Dao, L. N., Parikh, S. A., Shanafelt, T. D., Call, T. G., Ansell, S. M., Leis, J. F., Mai, M., Hanson, C. A. & Rech, K. L., Jan 1 2018, In : American Journal of Surgical Pathology. 42, 7, p. 843-854 12 p.

Research output: Contribution to journalArticle

6 Scopus citations

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

Abeykoon, J. P., Zanwar, S., Ansell, S. M., Winters, J., Gertz, M., King, R., Murray, D., Habermann, T. M., Dingli, D. M., Muchtar, E., Go, R. S., Leung, N., Inwards, D. J., Buadi, F. K., Dispenzieri, A., Lacy, M., Lin, Y., Gonsalves, W., Kourelis, T., Witzig, T. E. & 5 others, Thompson, C. A., Rajkumar, S. V., Kyle, R. A., Kumar, S. K. & Kapoor, P., Jan 1 2018, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

3 Scopus citations

Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma

Mackrides, N., Chapman, J., Larson, M. C., Ramos, J. C., Toomey, N., Lin, P., Maurer, M. J., Rafaelle, M., Tan, Y., Ikpatt, O., Syrbu, S., Ansell, S. M., Habermann, T. M., Link, B. K., Feldman, A. L., Lossos, I. S., Cerhan, J. R. & Vega, F., Jan 1 2018, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

2 Scopus citations

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia

Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M., Dispenzieri, A., Muchtar, E., Sidana, S., Tandon, N., Rajkumar, S. V., Dingli, D. M., Go, R., Lacy, M., Kourelis, T., Witzig, T. E., Inwards, D., Buadi, F., Gonsalves, W., Habermann, T. M., Johnston, P. B., Nowakowski, G. S. & 3 others, Kyle, R. A., Kumar, S. K. & Kapoor, P., Jan 1 2018, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

4 Scopus citations

Reply to Castillo et al.

Abeykoon, J. P., King, R., Ansell, S. M., Rajkumar, S. V., Paludo, J., Kyle, R. A., Kumar, S. K., Gertz, M. & Kapoor, P., Mar 1 2018, In : American Journal of Hematology. 93, 3, p. E71-E73

Research output: Contribution to journalLetter

2 Scopus citations

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: A phase 2 consortium trial

Bartlett, N. L., Costello, B., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C., Qi, J., Siegel, B. A., Griffith, M., Griffith, O. L., Gomez, F. & Fehniger, T. A., Jan 11 2018, In : Blood. 131, 2, p. 182-190 9 p.

Research output: Contribution to journalArticle

36 Scopus citations

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Jalali, S., Price-Troska, T., Paludo, J., Villasboas, J., Kim, H. J., Yang, Z. Z., Novak, A. J. & Ansell, S. M., Aug 14 2018, In : Blood Advances. 2, 15, p. 1985-1997 13 p.

Research output: Contribution to journalArticle

Open Access
7 Scopus citations

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells

Paulus, A., Manna, A., Akhtar, S., Paulus, S. M., Sharma, M., Coignet, M. V., Jiang, L., Roy, V., Witzig, T. E., Ansell, S. M., Allan, J., Furman, R., Aulakh, S., Manochakian, R., Ailawadhi, S., Chanan Khan, A. A. & Sher, T., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

2 Scopus citations

Targeting myddosome signaling in Waldenstrom's macroglobulinemia with the interleukin-1 receptor-associated kinase 1/4 inhibitor R191

Ni, H., Shirazi, F., Baladandayuthapani, V., Lin, H., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Hitoshi, Y., Ansell, S. M., Treon, S. P., Thomas, S. K., Lee, H. C., Wang, Z., Eric Davis, R. & Orlowski, R. Z., Dec 15 2018, In : Clinical Cancer Research. 24, 24, p. 6408-6420 13 p.

Research output: Contribution to journalArticle

2 Scopus citations

T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines

Horwitz, S. M., Ansell, S. M., Ai, W. Z., Barnes, J., Barta, S. K., Choi, M., Clemens, M. W., Dogan, A., Greer, J. P., Halwani, A., Bradley, M. H., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Kim, Y. H., Lunning, M. A., Mehta, A., Mehta-Shah, N., Oki, Y., Olsen, E. A. & 11 others, Pro, B., Rajguru, S. A., Shanbhag, S., Shustov, A., Sokol, L., Torka, P., Wilcox, R., William, B., Zain, J., Dwyer, M. A. & Sundar, H., Feb 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 2, p. 123-135 13 p.

Research output: Contribution to journalReview article

14 Scopus citations

The Bone Marrow Microenvironment in Waldenström Macroglobulinemia

Jalali, S. & Ansell, S. M., Jan 1 2018, (Accepted/In press) In : Hematology/Oncology Clinics of North America.

Research output: Contribution to journalArticle

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia

McMaster, M. L., Berndt, S. I., Zhang, J., Slager, S. L., Li, S. A., Vajdic, C. M., Smedby, K. E., Yan, H., Birmann, B. M., Brown, E. E., Smith, A., Kleinstern, G., Fansler, M. M., Mayr, C., Zhu, B., Chung, C. C., Park, J. H., Burdette, L., Hicks, B. D., Hutchinson, A. & 61 others, Teras, L. R., Adami, H. O., Bracci, P. M., McKay, J., Monnereau, A., Link, B. K., Vermeulen, R. C. H., Ansell, S. M., Maria, A., Diver, W. R., Melbye, M., Ojesina, A. I., Kraft, P., Boffetta, P., Clavel, J., Giovannucci, E., Besson, C. M., Canzian, F., Travis, R. C., Vineis, P., Weiderpass, E., Montalvan, R., Wang, Z., Yeager, M., Becker, N., Benavente, Y., Brennan, P., Foretova, L., Maynadie, M., Nieters, A., de Sanjose, S., Staines, A., Conde, L., Riby, J., Glimelius, B., Hjalgrim, H., Pradhan, N., Feldman, A. L., Novak, A. J., Lawrence, C., Bassig, B. A., Lan, Q., Zheng, T., North, K. E., Tinker, L. F., Cozen, W., Severson, R. K., Hofmann, J. N., Zhang, Y., Jackson, R. D., Morton, L. M., Purdue, M. P., Chatterjee, N., Offit, K., Cerhan, J. R., Chanock, S. J., Rothman, N., Vijai, J., Goldin, L. R., Skibola, C. F. & Caporaso, N. E., Dec 1 2018, In : Nature communications. 9, 1, 4182.

Research output: Contribution to journalArticle

2 Scopus citations

Waldenström macroglobulinemia

Fonseca, R. & Ansell, S. M., Nov 19 2018, Wintrobe's Clinical Hematology: Fourteenth Edition. Wolters Kluwer Health Pharma Solutions (Europe) Ltd, p. 6625-6649 25 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

2017

Acalabrutinib in mantle cell lymphoma

Kapoor, P. & Ansell, S. M., Jan 1 2017, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

3 Scopus citations

Advances in the understanding of IgM monoclonal gammopathy of undetermined significance

Paludo, J. & Ansell, S. M., Jan 1 2017, In : F1000Research. 6, 2142.

Research output: Contribution to journalReview article

2 Scopus citations

Anti-CD20-IL-21 fusokine: The tail wags the dog

Ansell, S. M., Apr 20 2017, In : Blood. 129, 16, p. 2209-2210 2 p.

Research output: Contribution to journalComment/debate

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma

Dispenzieri, A., D'Souza, A., Gertz, M., Laumann, K., Wiseman, G., Lacy, M., LaPlant, B., Buadi, F., Hayman, S. R., Kumar, S. K., Dingli, D. M., Hogan, W., Ansell, S. M., Gastineau, D. A., Inwards, D. J., Micallef, I., Porrata, L. F., Johnston, P. B., Litzow, M. R. & Witzig, T. E., Oct 1 2017, In : Bone Marrow Transplantation. 52, 10, p. 1372-1377 6 p.

Research output: Contribution to journalArticle

1 Scopus citations

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

Rosenthal, A., Dueck, A., Ansell, S. M., Gano, K., Conley, C., Nowakowski, G. S., Camoriano, J. K., Leis, J. F., Mikhael, J. R., Stewart, A. K., Inwards, D., Dingli, D. M., Kumar, S. K., Noel, P., Gertz, M., Porrata, L., Russell, S. J., Colgan, J., Fonseca, R., Habermann, T. M. & 6 others, Kapoor, P., Buadi, F., Leung, N., Tiedemann, R., Witzig, T. E. & Reeder, C., May 1 2017, In : American Journal of Hematology. 92, 5, p. 467-472 6 p.

Research output: Contribution to journalArticle

5 Scopus citations
4 Scopus citations

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

Farooq, U., Maurer, M. J., Thompson, C. A., Thanarajasingam, G., Inwards, D. J., Micallef, I., Macon, W., Syrbu, S., Lin, T., Lin, Y., Ansell, S. M., Nowakowski, G. S., Habermann, T. M., Cerhan, J. R. & Link, B. K., Oct 1 2017, In : British Journal of Haematology. 179, 1, p. 50-60 11 p.

Research output: Contribution to journalArticle

15 Scopus citations
18 Scopus citations

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia

Paludo, J., Abeykoon, J. P., Kumar, S., Shreders, A., Ailawadhi, S., Gertz, M. A., Kourelis, T., King, R. L., Reeder, C. B., Leung, N., Kyle, R. A., Buadi, F. K., Habermann, T. M., Dingli, D., Witzig, T. E., Dispenzieri, A., Lacy, M. Q., Go, R. S., Lin, Y., Gonsalves, W. I. & 5 others, Warsame, R., Lust, J. A., Rajkumar, S. V., Ansell, S. M. & Kapoor, P., Oct 2017, In : British journal of haematology. 179, 1, p. 98-105 8 p.

Research output: Contribution to journalArticle

6 Scopus citations
50 Scopus citations